Company Profile: Surface Oncology
(WorldNews Health)

Surface Oncology (NASDAQ:SURF) is a clinical-stage biopharmaceutical company with clinical assets targeting CD47 and CD73. If you are a new investor to the CD47 story, I recommend you start here. Clinical Pipeline SURF has two compounds in ongoing phase 1 trials, SRF-231 and SRF-373, with two more compounds expected to enter clinical development by 2020. No clinical results have been reported thus far. Source: Investor Update, June 2018 SRF-231 The SRF-231 antibody is very similar to other antibodies targeting CD47 in clinical development. It consists of an IgG4 Fc domain with limited effector function and a variable binding domain. In preclinical models, SRF-231 has been shown to not induce...